In Coding
Oct 1st, 2010
New dosage and administration technique recommendations for FASLODEX® were approved by the U.S. Food and Drug Administration (FDA) Sept. 10. New Dosing for FASLODEX Injections was last modified: July 5th, 2011 by admin aapc...
In Coding
Oct 1st, 2010
The U.S. Food and Drug Administration (FDA) approved Krystexxa (pegloticase) Sept. 14 to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy. Gout, which falls under ICD-9-CM diagnosis code 274.x, occurs due to an excess of the bodily waste uric acid, which is eventually ...